Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2026

Accounting Policies [Abstract]

Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share

Potentially dilutive securities, which are not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:

	As of September 30,
	2026	2025
Options to purchase common stock	6,735,314	2,572,850
Placement agent warrants	28,333	28,333
Time based Stock Appreciation Rights	418,722	499,977
Stock Appreciation Rights from exercised Series B Warrants	100,059	—
Potential additional Stock Appreciation Rights from Series B Warrants	280,783	999,953
Potential Stock Appreciation Rights from Series A Warrants	—	999,953
Series A Warrants	—	8,666,667
Series B Warrants	2,557,967	8,666,667
Tranche 2 Share rights	—	4,662,005
Tranche 3 Share rights	—	4,662,005
Potential Tranche 2 SARs	—	499,977
Potential Tranche 3 SARs	—	499,977
February 2026 common warrants	22,294,900	—
	32,416,078	32,758,364